Literature DB >> 11212100

The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist.

J E Macor1, D Gurley, T Lanthorn, J Loch, R A Mack, G Mullen, O Tran, N Wright, J C Gordon.   

Abstract

The 5-HT3 receptor antagonist tropisetron (ICS 205-930) was found to be a potent and selective partial agonist at alpha7 nicotinic receptors. Two other 5-HT3 receptor antagonists, ondansetron and LY-278,584, were found to lack high affinity at the alpha7 nicotinic receptor. Quinuclidine analogues (1 and 2) of tropisetron were also found to be potent and selective partial agonists at alpha7 nicotinic receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11212100     DOI: 10.1016/s0960-894x(00)00670-3

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  49 in total

1.  VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.

Authors:  A J Thompson; M H P Verheij; I J P de Esch; S C R Lummis
Journal:  J Pharmacol Exp Ther       Date:  2012-02-03       Impact factor: 4.030

2.  Creating an α7 nicotinic acetylcholine recognition domain from the acetylcholine-binding protein: crystallographic and ligand selectivity analyses.

Authors:  Akos Nemecz; Palmer Taylor
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

Review 3.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

4.  The multi-functional drug tropisetron binds APP and normalizes cognition in a murine Alzheimer's model.

Authors:  Patricia Spilman; Olivier Descamps; Olivia Gorostiza; Clare Peters-Libeu; Karen S Poksay; Alexander Matalis; Jesus Campagna; Alexander Patent; Rammohan Rao; Varghese John; Dale E Bredesen
Journal:  Brain Res       Date:  2013-12-31       Impact factor: 3.252

Review 5.  Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Authors:  Karin R Tietje; David J Anderson; R Scott Bitner; Eric A Blomme; Paul J Brackemeyer; Clark A Briggs; Kaitlin E Browman; Dagmar Bury; Peter Curzon; Karla U Drescher; Jennifer M Frost; Ryan M Fryer; Gerard B Fox; Jens Halvard Gronlien; Monika Håkerud; Earl J Gubbins; Sabine Halm; Richard Harris; Rosalind J Helfrich; Kathy L Kohlhaas; Devalina Law; John Malysz; Kennan C Marsh; Ruth L Martin; Michael D Meyer; Angela L Molesky; Arthur L Nikkel; Stephani Otte; Liping Pan; Pamela S Puttfarcken; Richard J Radek; Holly M Robb; Eva Spies; Kirsten Thorin-Hagene; Jeffrey F Waring; Hilde Ween; Hongyu Xu; Murali Gopalakrishnan; William H Bunnelle
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 7.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

8.  Selective breeding for high alcohol preference increases the sensitivity of the posterior VTA to the reinforcing effects of nicotine.

Authors:  Sheketha R Hauser; Amy L Bracken; Gerald A Deehan; Jamie E Toalston; Zheng-Ming Ding; William A Truitt; Richard L Bell; William J McBride; Zachary A Rodd
Journal:  Addict Biol       Date:  2013-03-18       Impact factor: 4.280

Review 9.  High throughput electrophysiology with Xenopus oocytes.

Authors:  Roger L Papke; Cathy Smith-Maxwell
Journal:  Comb Chem High Throughput Screen       Date:  2009-01       Impact factor: 1.339

10.  Expression of gLTP in sympathetic ganglia of obese Zucker rats in vivo: molecular evidence.

Authors:  K H Alzoubi; A M Aleisa; K A Alkadhi
Journal:  J Mol Neurosci       Date:  2008-06-19       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.